Biosimilars: Some Patient And Prescriber Groups Appear To Warm Up To Arbitrary Suffixes

The US FDA has approved 20 biosimilars, all but one with an arbitrary suffix. Some patient and prescriber groups are now warming up to the nomencature.

More from Biosimilars

More from Biosimilars & Generics